Raloxifene nanomicelles reduce the growth of castrate-resistant prostate cancer
作者： Tara Pritchard , Rhonda J. Rosengren , Khaled Greish , Sebastien Taurin
DOI: 10.3109/1061186X.2015.1086360
关键词:
摘要: AbstractBackground: Castrate-resistant prostate cancer (CRPC) patients are characterised by a 5-year relative survival rate of ∼25–33%. Recently, our laboratory encapsulated selective oestrogen receptor modulator, raloxifene, into poly(styrene-co-maleic acid) (SMA-raloxifene), which demonstrated superior in vitro cytotoxicity compared with free drug against several CRPC cell lines.Purpose: To validate SMA-raloxifene for the management using mouse xenograft model.Methods: The internalisation and retention micellar raloxifene were measured HPLC. A PC3-CRPC model was used to compare biodistribution both formulations, as well their effect on tumour progression where mice received (1 or 5 mg/kg, i.v.) (1 mg/kg, weekly 4 weeks.Results: exhibited 75% higher intracellular content after 48 h PC3 cells. Biodistribution 69% tumours followin...
sci-hub.se 参考文章(61)
Susan M. Henshall, Jan-Ake Gustafsson, Phillip D. Stricker, Phillip C. Brenner, Sari Makela, Robert L. Sutherland, David I. Quinn, Lisa G. Horvath, Raji Kooner, David Golovsky, John J. Grygiel, Gordon O’Neill, Warick Delprado, Darren R. Head, C-Soon Lee, Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer Cancer Research. ,vol. 61, pp. 5331- 5335 ,(2001)
Do Hwan Seong, Isaac Yi Kim, Young Jin Hong, Dug Keun Lee, Ronald A. Morton, Jeong Meen Seo, Byung Chul Kim, Heung Tae Kim, Seong Jin Kim, Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research. ,vol. 62, pp. 5365- 5369 ,(2002)
Alan T Remaley, Do Hwan Seong, Isaac Yi Kim, Seong-Jin Kim, Dug Keun Lee, Ronald A Morton, Fredrick Leach, Byung-Chul Kim, Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research. ,vol. 62, pp. 3649- 3653 ,(2002)
Peter S. Amenta, Gregory F. Sullivan, Jin Ming Yang, Jocelyn D. Villanueva, Carmelita J. Alvarez, William N. Hait, The expression of drug resistance gene products during the progression of human prostate cancer. Clinical Cancer Research. ,vol. 4, pp. 1393- 1403 ,(1998)
H Zincke, E J Bergstralh, M L Blute, R P Myers, D M Barrett, M M Lieber, S K Martin, J E Oesterling, Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. Journal of Clinical Oncology. ,vol. 12, pp. 2254- 2263 ,(1994) , 10.1200/JCO.1994.12.11.2254
Yasuhiro Matsumura, Hiroshi Maeda, A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs Cancer Research. ,vol. 46, pp. 6387- 6392 ,(1986)
Nate Larson, Khaled Greish, Hillevi Bauer, Hiroshi Maeda, Hamidreza Ghandehari, Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin International Journal of Pharmaceutics. ,vol. 420, pp. 111- 117 ,(2011) , 10.1016/J.IJPHARM.2011.08.011
Aleš Mrhar, Bruno Stieger, Gerd A. Kullak-Ublick, Janja Marc, Barbara Ostanek, Andrej Zavratnik, Albin Kristl, Katja Berginc, Katja Delić, Jurij Trontelj, Tina Trdan Lušin, Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment Translational Research. ,vol. 160, pp. 298- 308 ,(2012) , 10.1016/J.TRSL.2012.03.002
Madhu Burra, Raju Jukanti, Karthik Yadav Janga, Sharath Sunkavalli, Ashok Velpula, Srinivas Ampati, K.N. Jayaveera, Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles Advanced Powder Technology. ,vol. 24, pp. 393- 402 ,(2013) , 10.1016/J.APT.2012.09.002
Punna Rao Ravi, N. Aditya, Himanshu Kathuria, Srinivas Malekar, Rahul Vats, Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. European Journal of Pharmaceutics and Biopharmaceutics. ,vol. 87, pp. 114- 124 ,(2014) , 10.1016/J.EJPB.2013.12.015